BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38356704)

  • 1. Programmed cell death-index (PCDi) as a prognostic biomarker and predictor of drug sensitivity in cervical cancer: a machine learning-based analysis of mRNA signatures.
    Wang W; Chen P; Yuan S
    J Cancer; 2024; 15(5):1378-1396. PubMed ID: 38356704
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.
    Shi Y; Feng Y; Qiu P; Zhao K; Li X; Deng Z; Wang J
    Front Immunol; 2023; 14():1298290. PubMed ID: 38170006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
    Wu Z; Jin M; Xin P; Zhang H
    Front Immunol; 2023; 14():1293729. PubMed ID: 38146369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy.
    Wang S; Wang R; Hu D; Zhang C; Cao P; Huang J
    NPJ Precis Oncol; 2024 Feb; 8(1):49. PubMed ID: 38409471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma.
    He Z; Zhang J; Huang W
    Sci Rep; 2023 Nov; 13(1):20509. PubMed ID: 37993470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of machine learning for developing a prognostic signature related to programmed cell death in colorectal cancer.
    Xu QT; Qiang JK; Huang ZY; Jiang WJ; Cui XM; Hu RH; Wang T; Yi XL; Li JY; Yu Z; Zhang S; Du T; Liu J; Jiang XH
    Environ Toxicol; 2024 May; 39(5):2908-2926. PubMed ID: 38299230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
    Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
    J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
    Li Z; Li Y; Liu L; Zhang C; Li X
    Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing chemotherapy and targeted therapy in liver hepatocellular carcinoma.
    Pan Y; Zhu Q; Hong T; Cheng J; Tang X
    Aging (Albany NY); 2024 May; 16():. PubMed ID: 38787389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
    Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
    Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
    Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicineĀ and based on a 101-combination machine learning computational framework.
    Liu J; Shi Y; Zhang Y
    EPMA J; 2023 Jun; 14(2):275-305. PubMed ID: 37275552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.
    Lan Y; Jia Q; Feng M; Zhao P; Zhu M
    Front Genet; 2023; 14():1100020. PubMed ID: 37035749
    [No Abstract]   [Full Text] [Related]  

  • 15. Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer.
    Zhang L; Peng M
    Front Immunol; 2022; 13():1030097. PubMed ID: 36505448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer.
    Song X; Hou L; Zhao Y; Guan Q; Li Z
    Front Pharmacol; 2022; 13():1039499. PubMed ID: 36339625
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
    Yu Y; Lou Y; Zhu J; Wang X
    Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
    Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
    Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
    Xu HH; Wang HL; Xing TJ; Wang XQ
    Front Immunol; 2022; 13():851622. PubMed ID: 35924232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.